Unigestion Holding SA lessened its holdings in Iqvia Holdings Inc (NYSE:IQV) by 81.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,042 shares of the medical research company’s stock after selling 188,869 shares during the quarter. Unigestion Holding SA’s holdings in Iqvia were worth $5,714,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of IQV. First Trust Advisors LP purchased a new position in Iqvia in the 2nd quarter worth $99,127,000. Laurion Capital Management LP raised its position in Iqvia by 188.1% in the 2nd quarter. Laurion Capital Management LP now owns 378,318 shares of the medical research company’s stock worth $37,764,000 after purchasing an additional 807,697 shares during the period. USS Investment Management Ltd purchased a new position in Iqvia in the 3rd quarter worth $86,508,000. BlackRock Inc. raised its position in Iqvia by 5.7% in the 2nd quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock worth $1,015,173,000 after purchasing an additional 546,878 shares during the period. Finally, Atalanta Sosnoff Capital LLC purchased a new position in Iqvia in the 3rd quarter worth $51,970,000. Institutional investors own 91.36% of the company’s stock.
In other news, Director John G. Danhakl sold 370,470 shares of Iqvia stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John G. Danhakl sold 221,900 shares of Iqvia stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $126.63, for a total transaction of $28,099,197.00. The disclosure for this sale can be found here. Insiders have sold a total of 601,586 shares of company stock worth $75,510,422 in the last ninety days. Insiders own 6.00% of the company’s stock.
A number of equities research analysts have issued reports on IQV shares. Robert W. Baird raised their price target on shares of Iqvia from $143.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday, October 2nd. Raymond James raised their price target on shares of Iqvia from $136.00 to $145.00 and gave the stock a “strong-buy” rating in a report on Friday, August 31st. Royal Bank of Canada raised their price target on shares of Iqvia to $137.00 and gave the stock an “outperform” rating in a report on Tuesday, October 23rd. Morgan Stanley raised their price target on shares of Iqvia from $121.00 to $130.00 and gave the stock an “overweight” rating in a report on Wednesday, July 25th. Finally, Barclays raised their price target on shares of Iqvia from $130.00 to $140.00 and gave the stock an “overweight” rating in a report on Tuesday, October 23rd. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $131.67.
Shares of IQV opened at $124.17 on Friday. The stock has a market cap of $25.62 billion, a PE ratio of 24.97, a P/E/G ratio of 1.82 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. Iqvia Holdings Inc has a 1-year low of $91.57 and a 1-year high of $135.48.
Iqvia (NYSE:IQV) last announced its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. The firm had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The business’s revenue was up 5.2% compared to the same quarter last year. Research analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current year.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Read More: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.